Mira Pharmaceuticals (MIRA) Liabilities and Shareholders Equity (2022 - 2025)

Mira Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $11.1 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $11.1 million, up 279.52% year-over-year; the trailing twelve-month figure through Dec 2025 was $21.0 million (up 90.9% YoY), and the FY2025 annual result was $11.1 million, up 279.52% from the prior year.
• Liabilities and Shareholders Equity came in at $11.1 million for Q4 2025 at Mira Pharmaceuticals, up from $7.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $11.1 million in Q4 2025 to a low of $858074.0 in Q4 2022.
• The 4-year median for Liabilities and Shareholders Equity is $3.8 million (2023), against an average of $4.6 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 474.83% in 2023 and slumped 63.23% in 2025, its largest moves.
• Mira Pharmaceuticals' Liabilities and Shareholders Equity stood at $858074.0 in 2022, then jumped by 474.83% to $4.9 million in 2023, then slumped by 40.74% to $2.9 million in 2024, then surged by 279.52% to $11.1 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $11.1 million (Q4 2025), $7.6 million (Q3 2025), and $868318.0 (Q2 2025), per Business Quant data.